SHORELINE BIOSCIENCES TO PRESENT AT 2024 STIFEL HEALTHCARE CONFERENCE
Date
11/15/2024 4:16:01 PM
(MENAFN- PR Newswire)
SAN DIEGO, Nov. 15, 2024 /PRNewswire/ -- Shoreline Biosciences, Inc., a biopharmaceutical company developing disease modifying
iNK cell therapies for autoimmune disorders, today announced its participation in the 2024 Stifel Healthcare conference taking place November 18-19, 2024, in New York, NY.
Company management will present on Monday, November 18, 2024, at 4:45 pm ET and will also participate in one-on-one meetings with investors during the conference.
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing disease modifying iNK cell therapies for autoimmune disorders. Shoreline is advancing a pipeline of induced pluripotent stem cells (iPSC) derived natural killer cells (iNK) and macrophage (iMACs) therapies to deliver safe, affordable and accessible medicines. The Company's cellular design and gene editing technologies are built on a unique understanding of immune cell biology and premier gene editing tools such as SLEEK knock-in technology and access to AsCas12a, a high fidelity and high efficiency engineered
CRISPR/CAS endonuclease. Shoreline has also developed an industry-leading SMARTTM manufacturing platform to enable truly off the shelf and scalable cell therapies.
For more information, please visit
and engage with us on
LinkedIn .
SOURCE Shoreline Biosciences, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN15112024003732001241ID1108891421
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.